Factors associated with extremely poor visual outcomes in patients with central retinal vein occlusion.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 11 2020
12 11 2020
Historique:
received:
30
07
2020
accepted:
19
10
2020
entrez:
13
11
2020
pubmed:
14
11
2020
medline:
29
12
2020
Statut:
epublish
Résumé
Here, we examined prognostic factors for extremely poor visual outcomes in patients with central retinal vein occlusion (CRVO) in actual practices. We included 150 consecutive eyes with treatment-naïve acute CRVO from four different facilities and observed them for over 24 months. Macular edema (ME) was treated with one or three monthly anti-vascular endothelial growth factor injections (1 or 3 + pro re nata). According to the final Snellen visual acuity (VA), we divided the patients into very poor VA (< 20/200) and control (≥ 20/200) groups and examined risk factors for poor final visual outcomes. The baseline Snellen VA was hand motion to 20/13. The mean number of anti-VEGF injections for ME was 5.3 ± 3.7 during the follow-up period. In total, 49 (32.7%) patients exhibited a very poor final VA; this group comprised significantly older patients with a significantly poorer baseline VA (P < 0.01 for both) than the control group. Comorbid internal carotid artery disease and diabetic retinopathy were significantly associated with a poor final VA. In actual clinical practice, visual outcomes may be extremely poor despite ME treatment in certain patients with CRVO, with advanced age, poor baseline VA, and comorbid internal carotid artery disease and diabetic retinopathy being significant risk factors.
Identifiants
pubmed: 33184484
doi: 10.1038/s41598-020-76840-6
pii: 10.1038/s41598-020-76840-6
pmc: PMC7665063
doi:
Substances chimiques
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19667Références
Ophthalmology. 1983 May;90(5):488-506
pubmed: 6192376
Retina. 2014 Sep;34(9):1728-35
pubmed: 24914476
Arch Ophthalmol. 1996 May;114(5):545-54
pubmed: 8619763
Br J Ophthalmol. 2018 Aug;102(8):1066-1071
pubmed: 29699979
Br J Ophthalmol. 1965 Dec;49(12):626-45
pubmed: 4954984
Am J Ophthalmol. 1971 Nov;72(5):998-1011
pubmed: 5315812
Arch Ophthalmol. 2008 Apr;126(4):513-8
pubmed: 18413521
Sci Rep. 2019 Apr 25;9(1):6569
pubmed: 31024035
Retina. 2018 Feb;38(2):272-282
pubmed: 28221256
Ophthalmology. 2010 Jun;117(6):1124-1133.e1
pubmed: 20381871
Arch Ophthalmol. 1997 Apr;115(4):486-91
pubmed: 9109757
Am J Ophthalmol. 2019 Aug;204:62-69
pubmed: 30862502
BMJ Open Ophthalmol. 2020 Mar 24;5(1):e000423
pubmed: 32258421
Ophthalmology. 2011 Jan;118(1):119-133.e1-2
pubmed: 20723991
Ophthalmology. 2011 Oct;118(10):2041-9
pubmed: 21715011
Invest Ophthalmol Vis Sci. 1986 Dec;27(12):1706-12
pubmed: 2947873
Am J Ophthalmol. 2016 Aug;168:260-268
pubmed: 27296489
Retina. 2018 Aug;38(8):1571-1580
pubmed: 28671896
Arch Ophthalmol. 1993 Aug;111(8):1087-95
pubmed: 7688950
Am J Ophthalmol. 2013 Mar;155(3):429-437.e7
pubmed: 23218699
Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2708-2716
pubmed: 29860457
Ophthalmol Retina. 2018 Feb;2(2):134-142
pubmed: 31047340
Ophthalmology. 1983 May;90(5):458-74
pubmed: 6877778
Br J Ophthalmol. 2013 Mar;97(3):278-84
pubmed: 23298885
Ophthalmology. 2016 May;123(5):1101-11
pubmed: 26896124
Ophthalmology. 2012 May;119(5):1024-32
pubmed: 22440275
Ophthalmology. 1983 May;90(5):481-3
pubmed: 6877780